Cargando…
Ryanodine channel complex stabilizer compound S48168/ARM210 as a disease modifier in dystrophin-deficient mdx mice: proof-of-concept study and independent validation of efficacy
Muscle fibers lacking dystrophin undergo a long-term alteration of Ca(2+) homeostasis, partially caused by a leaky Ca(2+) release ryanodine (RyR) channel. S48168/ARM210, an RyR calcium release channel stabilizer (a Rycal compound), is expected to enhance the rebinding of calstabin to the RyR channel...
Autores principales: | Capogrosso, Roberta Francesca, Mantuano, Paola, Uaesoontrachoon, Kitipong, Cozzoli, Anna, Giustino, Arcangela, Dow, Todd, Srinivassane, Sadish, Filipovic, Marina, Bell, Christina, Vandermeulen, Jack, Massari, Ada Maria, De Bellis, Michela, Conte, Elena, Pierno, Sabata, Camerino, Giulia Maria, Liantonio, Antonella, Nagaraju, Kanneboyina, De Luca, Annamaria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Federation of American Societies for Experimental Biology
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888399/ https://www.ncbi.nlm.nih.gov/pubmed/29097503 http://dx.doi.org/10.1096/fj.201700182RRR |
Ejemplares similares
-
Effects of Dantrolene Therapy on Disease Phenotype in Dystrophin Deficient mdx Mice
por: Quinn, James L, et al.
Publicado: (2013) -
Biomarker-focused multi-drug combination therapy and repurposing trial in mdx mice
por: Ziemba, Michael, et al.
Publicado: (2021) -
Therapeutic Approaches to Genetic Ion Channelopathies and Perspectives in Drug Discovery
por: Imbrici, Paola, et al.
Publicado: (2016) -
Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy
por: Heier, Christopher R, et al.
Publicado: (2019) -
Metabolic remodeling agents show beneficial effects in the dystrophin-deficient mdx mouse model
por: Jahnke, Vanessa E, et al.
Publicado: (2012)